{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:08:50Z","timestamp":1789996130583,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Janssen Asia Pacific"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ijantimicag.2012.01.002","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T19:27:25Z","timestamp":1330975645000},"page":"311-316","source":"Crossref","is-referenced-by-count":71,"title":["Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study"],"prefix":"10.1016","volume":"39","author":[{"given":"Pattarachai","family":"Kiratisin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Chongthaleong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thean Yen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Lagamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemelyn","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jinf.2011.02.009","article-title":"Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria","volume":"62","author":"Chen","year":"2011","journal-title":"J Infect"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2012.01.002_bib0010","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/cc6820","article-title":"Gram-negative antibiotic resistance: there is a price to pay","volume":"12","author":"Slama","year":"2008","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0015","unstructured":"US Centers for Disease Control and Prevention. A public health action plan to combat antimicrobial resistance. http:\/\/www.cdc.gov\/drugresistance\/actionplan\/taskforce.html [accessed 6 May 2011]."},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2012.01.002_bib0020","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1093\/cid\/cir153","article-title":"Combating antimicrobial resistance: policy recommendations to save lives","volume":"52","author":"Infectious Diseases Society of America (IDSA)","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0025","series-title":"WHO global strategy for the containment of antimicrobial resistance","author":"World Health Organization","year":"2001"},{"issue":"4 Suppl.","key":"10.1016\/j.ijantimicag.2012.01.002_bib0030","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.ajic.2007.01.015","article-title":"Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group","volume":"36","author":"Song","year":"2008","journal-title":"Am J Infect Control"},{"issue":"4 Suppl.","key":"10.1016\/j.ijantimicag.2012.01.002_bib0035","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.ajic.2007.05.011","article-title":"Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries","volume":"36","author":"Chawla","year":"2008","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijantimicag.2008.07.031","article-title":"Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)","volume":"33","author":"Bouchillon","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"4 Suppl.","key":"10.1016\/j.ijantimicag.2012.01.002_bib0045","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.ajic.2007.10.020","article-title":"Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries","volume":"36","author":"Lagamayo","year":"2008","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0050","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/517954","article-title":"Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia","volume":"28","author":"Lee","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0055","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1128\/AAC.50.4.1257-1262.2006","article-title":"Clinical and economic impact of bacteremia with extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"50","author":"Schwaber","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum \u03b2-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0065","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/14656566.9.1.23","article-title":"Carbapenems: a potent class of antibiotics","volume":"9","author":"Nicolau","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0075","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1128\/AAC.00381-08","article-title":"In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States","volume":"52","author":"Pillar","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0080","series-title":"Program and abstracts of the 2nd World Conference on Magic Bullets (EHRLICH II)","article-title":"Doripenem, a new carbapenem: optimizing dose to treat increasingly resistant Gram-negative pathogens","author":"Nicholson","year":"2008"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0085","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1128\/AAC.01843-09","article-title":"Pharmacokinetic\u2013pharmacodynamic-model-guided doripenem dosing in critically ill patients","volume":"54","author":"Samtani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0090","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijantimicag.2010.08.002","article-title":"In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study","volume":"36","author":"Christiansen","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0095","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M07-A8","author":"Clinical and Laboratory Standards Institute","year":"2009"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0100","series-title":"Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0105","series-title":"Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement (June 2010 update). Document M100-S20-U","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijantimicag.2011.01.009","article-title":"High burden of antimicrobial resistance in Asia","volume":"37","author":"Jean","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/499819","article-title":"Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America","volume":"42","author":"Talbot","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0120","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1093\/jac\/dkr290","article-title":"Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007\u201309","volume":"66","author":"Davies","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0125","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2010.07.002","volume":"36","author":"Hsueh","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2012.01.002_bib0135","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jac\/dkr137","article-title":"Impact of antimicrobial stewardship in critical care: a systematic review","volume":"66","author":"Kaki","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T23:11:10Z","timestamp":1561417870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857912000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0924857912000313"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.01.002","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}